(Q42539264)

2 November 2017

title

A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study (English)

1 reference

2 November 2017

1 reference

1 reference

T Ekström

1

1 reference

2 November 2017

N Ringdal

2

1 reference

2 November 2017

P Tukiainen

3

1 reference

2 November 2017

E Runnerström

4

1 reference

2 November 2017

S Soliman

5

1 reference

2 November 2017

publication date

1 September 1998

1 reference

Annals of Allergy, Asthma & Immunology

2 November 2017

published in

1 reference

2 November 2017

volume

81

1 reference

2 November 2017

issue

3

1 reference

2 November 2017

page(s)

225-230

1 reference

Clinical pharmacology of long-acting beta-receptor agonists

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Effects of N-aralkyl substitution of β-agonists on α- and β-adrenoceptor subtypes: pharmacological studies and binding assays

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962816-5

7 January 2021

10.1016/S1081-1206(10)62816-5

Identifiers

DOI

1 reference

2 November 2017

1 reference